Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13871020 | 1.00 | MAPK1 (0.48) | MAPK1TP53SOS1NPC1RAB9A | |
| SCHEMBL17788470 | 0.84 | CSF1R (0.51) | MAPK1TP53NPC1RAB9AALDH1A1 | |
| SCHEMBL2903787 | 0.84 | GRM5 (0.42) | MAPK1TP53NPC1RAB9AALDH1A1 | |
| SCHEMBL4100053 | 0.82 | NPC1 (0.51) | MAPK1TP53NPC1RAB9AALDH1A1 | |
| SCHEMBL1844413 | 0.82 | MAPK1 (0.50) | MAPK1TP53NPC1RAB9AALDH1A1 | |
| SCHEMBL1544213 | 0.82 | MAPK1 (0.50) | MAPK1TP53NPC1RAB9AALDH1A1 | |
| SCHEMBL5483690 | 0.82 | NPC1 (0.48) | MAPK1TP53NPC1RAB9AALDH1A1 | |
| SCHEMBL16504181 | 0.82 | MAPK1 (0.50) | MAPK1TP53NPC1RAB9AALDH1A1 | |
| SCHEMBL14389104 | 0.79 | GRM5 (0.51) | MAPK1TP53NPC1RAB9AALDH1A1 | |
| SCHEMBL8232338 | 0.79 | TP53 (0.45) | MAPK1TP53NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212316-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | AstraZeneca AB (SE) | 2010-08-04 | — | — | EP | claimed |
| US-20090111821-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| WO-2009054794-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| US-20090111821-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111821-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111821-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009054794-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111821-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | MAPK1 1575/4885TP53 4884/4885SOS1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.